Broccoli Sprout Extract in Treating Patients With Transitional Cell Bladder Cancer Undergoing Surgery

Inclusion Criteria:

* Any patient eligible for superficial bladder cancer
* Patients must be considered fit for surgical resection with curative intent
* No chemotherapy, surgery (excluding transurethral resection of bladder tumor \[TURBT\], BCG or radiotherapy in the prior 4 weeks \[6 weeks for mitomycin C or interferon\])
* No previous treatment/ingestion with broccoli extracts
* Eastern Oncology Group (ECOG) performance status 0-2
* AST and ALT =\< 2.5 times ULN (upper limit of normal)
* Total bilirubin =\< 2.0 mg/dL
* Creatinine Clearance \>= 30 ml/min
* WBC \> 3000 mm\^3
* Absolute neutrophil count \> 1000/mm\^3
* Platelets \> 100,000/mm\^3
* All patients must sign a study-specific consent form indicating that they are aware of the investigational nature of this study

Exclusion Criteria:

* Have participated in any clinical trial involving conventional or investigational drugs or devices within the previous 4 weeks
* Prior radiation to the pelvis
* Intractable urinary tract infection that has not responded to antibiotic treatment
* Active, uncontrolled bacterial, viral, or fungal infection including HIV
* Have had major surgery within 4 weeks of starting therapy (not including placement of vascular access device or TURBT)
* Poor medical risk in the opinion of the treating oncologist due to non-malignant systemic disease
* Pregnant or lactating patients: patients must be postmenopausal or practicing an accepted form of birth control; for patients where pregnancy is a possibility, a pregnancy test will be required prior to initiation of therapy
* Have a history of myocardial infarction or angina pectoris/angina equivalent in the last 6 months (the patient may be on anti-anginal medications if the symptoms have been entirely controlled for greater than 6 months), or have uncontrolled congestive heart failure
* Have a history of bleeding disorders or thrombosis; patients on therapeutic doses of anticoagulation (including coumadin or heparins) are not permitted on trial (this exclusion criterion does not include those patients receiving low dose or prophylactic dose anticoagulation \[i.e. coumadin 1 mg daily in patients with central intravenous lines\])
* Radiotherapy during the course of the trial
* Inability to tolerate proposed treatment or procedures
* Have additional uncontrolled serious medical conditions or psychiatric illness
* Patients with a history of hepatitis (including but not exclusive to viral hepatitis auto-immune or alcoholic)
* Patients with active thyroid disease (patients with hypothyroidism, adequately replaced on a stable dose of thyroid replacement will be allowed on trial)